Status:
COMPLETED
Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Nausea
Vomiting
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine the efficacy and tolerability of an investigational drug for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic ...
Eligibility Criteria
Inclusion
- Patient with a diagnosis of breast cancer requiring treatment with non-cisplatin moderately emetogenic chemotherapy.
- Patient must have completed participation in the main study for this protocol.
Exclusion
- Patient has a central nervous system malignancy.
- Patient will receive radiation to the abdomen or pelvis.
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2004
Estimated Enrollment :
820 Patients enrolled
Trial Details
Trial ID
NCT00092196
Start Date
December 1 2002
End Date
December 1 2004
Last Update
May 5 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.